


Invitation

Targeting KRAS in NSCLC: the path to optimising therapy

Saturday 20 November 2021 / 17.00–18.30 SGT / Channel 1



Faculty:



Tony Mok



Tony Lim



Tetsuya Mitsudomi

Programme:

- **Welcome and introduction**
Tony Mok, Chinese University of Hong Kong, Hong Kong
- **Targeting the undruggable: what we know about KRAS-mutant NSCLC**
Tetsuya Mitsudomi, Kindai University, Japan
- **Optimising biomarker testing for patients with NSCLC in Asia**
Tony Lim, Singapore General Hospital, Singapore
- **Expanding treatment options for patients with KRAS G12C-mutant NSCLC**
Tony Mok, Chinese University of Hong Kong, Hong Kong
- **Panel discussion**
All

AMGEN[®]

Oncology

Amgen Biotechnology Singapore Pte. Ltd.
3 Fraser Street, #15-26/27 DUO Tower,
Singapore 189352

SC-SGP-AMG 510-00013
Date of preparation: September 2021